No Data
No Data
InventisBio (SHSE:688382) Is In A Strong Position To Grow Its Business
Summary of Yifang Biotechnology's 2024 semi-annual report
Yifang Biology 2024 Half-Year Report
Yifang Biological (688382.SH): a net loss of 0.214 billion yuan in the first half of the year.
On August 22, Geelong reported that Yifang Life Sciences (688382.SH) released its 2024 interim report. During the reporting period, the company achieved revenue of 14.8732 million yuan, a decrease of 81.41% year-on-year; net income attributable to the company's shareholders was -0.214 billion yuan.
After Losing 40% in the Past Year, InventisBio Co., Limited (SHSE:688382) Institutional Owners Must Be Relieved by the Recent Gain
Yifang Biotechnology (688382.SH): The new drug Garsorasib is currently undergoing CDE review and approval for market launch.
On July 18th, Gelunhui investor asked Yifang Biotechnology (688382.SH) on the investor interactive platform, "Do we need to provide additional materials for CDE drug review of the cancer drug Gercysib?" The company replied that the new drug application for Garsorasib is currently undergoing CDE review process.
No Data
No Data